The vaxx - 10 fold increase in neurological problems

No Increased Risk of Neurological Conditions After COVID-19 Vaccination

March 17, 2022

A study of over 8 million participants found no correlation between COVID-19 vaccination and developing neurological conditions. However, a risk of some neurological conditions was increased after COVID-19 infection.

The approved vaccines are highly effective against preventing severe COVID-19 disease, hospitalization, and death. However, the rapid rollout of the vaccines left some unanswered questions about the long-term effects of COVID-19 vaccination.

One study, published today in The BMJ, examined the association between COVID-19 vaccines, COVID-19 infection, and risk of immune meditated neurological events. The investigators looked for evidence of 4 neurological conditions: Bell’s palsy (facial weakness), encephalomyelitis (inflammation of the brain and spinal cord), Guillain-Barré syndrome (a nerve condition), and transverse myelitis (inflammation of the spinal cord).

The study included 8330497 people who received at least 1 dose of a COVID-19 vaccine by January 13, 2022, ascertained from primary care records in the UK and Spain. At the time, there were 5 COVID-19 vaccines authorized by the European Medicines Agency, including the Pfizer-BioNTech and Moderna mRNA vaccines, the Oxford-AstraZeneca and Janssen viral vector vaccines, and the recombinant spike protein nanoparticle vaccine Novavax.

Overall, 4376535 people received AstraZeneca, 3588318 received Pfizer-BioNTech, 244913 received Moderna, and 120731 received Janssen. The study also included a total of 735870 unvaccinated people infected with COVID-19, and 14330080 people from the general population, studied retroactively to estimate historical background pre-pandemic.

The patient primary care records came from The Clinical Practice Research Datalink (CPRD) AURUM in the UK, and the Information System for Research in Primary Care (SIDIAP) database in Spain.

Post-vaccination rates of Bell’s palsy, encephalomyelitis and Guillain-Barré syndrome were consistent with rates established from the background study cohort. Transverse myelitis events were < 5 in all vaccinated groups and could not be analyzed.

Notably, rates of Bell’s palsy, encephalomyelitis and Guillain-Barré syndrome were all higher than anticipated after COVID-19 infection. The study was not causational, so the investigators did not speculate on why this was.
  • Broken down by individual risk the increased likelihood of developing a neurological condition after COVID-19 infection was small, but even a small risk can burden the healthcare system.
The results from such large studies show that neurological conditions are no more common among vaccinated people than among unvaccinated people (without prior COVID-19 infection). “We may never be able to tell exactly what caused an individual to develop a neurological condition, but COVID-19 vaccination is a highly unlikely reason for most,” the investigators concluded.
Published Study of Neurological Problems after Vaccination

Vaccination-Associated-Neurological-Problems.png


Conclusion

We found no safety signal for any of the studied immune mediated neurological events after vaccination against covid-19. Infection with SARS-CoV-2 was, however, associated with an increased risk of Bell’s palsy, encephalomyelitis, and Guillain-Barré syndrome.

References
  1. ↵
    WHO. COVID-19 Dashboard. Geneva: World Health Organization, 2020. https://covid19.who.int (accessed 14 January 2022).

  2. ↵
    European Medicines Agency. COVID-19 vaccines: authorised. www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised#authorised-covid-19-vaccines-section (accessed 14 January 2022).

  3. ↵
    1. Polack FP,
    2. Thomas SJ,
    3. Kitchin N,
    4. et al.,
    5. C4591001 Clinical Trial Group
    . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med2020;383:2603-15.doi:10.1056/NEJMoa2034577. pmid:33301246
    CrossRefPubMedGoogle Scholar
  4. ↵
    1. Baden LR,
    2. El Sahly HM,
    3. Essink B,
    4. et al.,
    5. COVE Study Group
    . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med2021;384:403-16.doi:10.1056/NEJMoa2035389. pmid:33378609
    CrossRefPubMedGoogle Scholar
  5. ↵
    1. Voysey M,
    2. Clemens SAC,
    3. Madhi SA,
    4. et al.,
    5. Oxford COVID Vaccine Trial Group
    . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet2021;397:99-111.doi:10.1016/S0140-6736(20)32661-1. pmid:33306989
    CrossRefPubMedGoogle Scholar
  6. ↵
    1. Sadoff J,
    2. Gray G,
    3. Vandebosch A,
    4. et al.,
    5. ENSEMBLE Study Group
    . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med2021;384:2187-201.doi:10.1056/NEJMoa2101544. pmid:33882225
    CrossRefPubMedGoogle Scholar
  7. ↵
    1. Heath PT,
    2. Galiza EP,
    3. Baxter DN,
    4. et al.,
    5. 2019nCoV-302 Study Group
    . Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med2021;385:1172-83.doi:10.1056/NEJMoa2107659. pmid:34192426
    CrossRefPubMedGoogle Scholar
  8. ↵
    European Medicines Agency. COVID-19 Vaccine Janssen: Guillain-Barré syndrome listed as a very rare side effect. www.ema.europa.eu/en/news/covid-19-vaccine-janssen-guillain-barre-syndrome-listed-very-rare-side-effect (accessed 19 October 2021).

  9. ↵
    1. Matarneh AS,
    2. Al-Battah AH,
    3. Farooqui K,
    4. Ghamoodi M,
    5. Alhatou M
    . COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect. Clin Case Rep2021;9:e04756.doi:10.1002/ccr3.4756. pmid:34484780
    CrossRefPubMedGoogle Scholar
  10. ↵
    1. Razok A,
    2. Shams A,
    3. Almeer A,
    4. Zahid M
    . Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar. Ann Med Surg (Lond)2021;67:102540.doi:10.1016/j.amsu.2021.102540. pmid:34249353
    CrossRefPubMedGoogle Scholar
  11. ↵
    1. Waheed S,
    2. Bayas A,
    3. Hindi F,
    4. Rizvi Z,
    5. Espinosa PS
    . Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine. Cureus2021;13:e13426.doi:10.7759/cureus.13426. pmid:33758714
    CrossRefPubMedGoogle Scholar
  12. ↵
    1. Hughes DL,
    2. Brunn JA,
    3. Jacobs J,
    4. Todd PK,
    5. Askari FK,
    6. Fontana RJ
    . Guillain-Barré syndrome after COVID-19 mRNA vaccination in a liver transplantation recipient with favorable treatment response. Liver Transpl2022;28:134-7.doi:10.1002/lt.26279. pmid:34431208
    CrossRefPubMedGoogle Scholar
  13. ↵
    1. Goss AL,
    2. Samudralwar RD,
    3. Das RR,
    4. Nath A,
    5. ANA Investigates
    . ANA Investigates: Neurological Complications of COVID-19 Vaccines. Ann Neurol2021;89:856-7.doi:10.1002/ana.26065. pmid:33710649
    CrossRefPubMedGoogle Scholar
  14. ↵
    1. Román GC,
    2. Gracia F,
    3. Torres A,
    4. Palacios A,
    5. Gracia K,
    6. Harris D
    . Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222). Front Immunol2021;12:653786.doi:10.3389/fimmu.2021.653786. pmid:33981305
    CrossRefPubMedGoogle Scholar
  15. ↵
    1. Nishizawa Y,
    2. Hoshina Y,
    3. Baker V
    . Bell’s palsy following the Ad26.COV2.S COVID-19 vaccination. QJM2021;114:657-8.doi:10.1093/qjmed/hcab143. pmid:34014316
    CrossRefPubMedGoogle Scholar
  16. ↵
    1. Zuhorn F,
    2. Graf T,
    3. Klingebiel R,
    4. Schäbitz WR,
    5. Rogalewski A
    . Postvaccinal Encephalitis after ChAdOx1 nCov-19. Ann Neurol2021;90:506-11.doi:10.1002/ana.26182. pmid:34324214
    CrossRefPubMedGoogle Scholar
  17. ↵
    1. Vogrig A,
    2. Janes F,
    3. Gigli GL,
    4. et al
    . Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination. Clin Neurol Neurosurg2021;208:106839.doi:10.1016/j.clineuro.2021.106839. pmid:34325334
    CrossRefPubMedGoogle Scholar
  18. ↵
    1. Wolf A,
    2. Dedman D,
    3. Campbell J,
    4. et al
    . Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol2019;48:1740-1740g, g.doi:10.1093/ije/dyz034. pmid:30859197
    CrossRefPubMedGoogle Scholar
  19. ↵
    1. Herrett E,
    2. Gallagher AM,
    3. Bhaskaran K,
    4. et al
    . Data resource profile: Clinical practice research datalink (CPRD). Int J Epidemiol2015;44:827-36.doi:10.1093/ije/dyv098. pmid:26050254
    CrossRefPubMedGoogle Scholar
  20. ↵
    Clinical Practice Research Datalink. CPRD Aurum June 2021 (Version 2021.06.001). Clinical Practice Research Datalink. June 7,2021.doi:10.48329/PYC2-WE97
    CrossRefGoogle Scholar
  21. ↵
    Burn E, Fernández-Bertolín S, Voss EA, et al. Establishing and characterising large COVID-19 cohorts after mapping the Information System for Research in Primary Care in Catalonia to the OMOP Common Data Model. MedRxiv 2021:21266734. [cited 2021 Jan 5]doi:10.1101/2021.11.23.21266734.
    Abstract/FREE Full TextGoogle Scholar
  22. ↵
    1. Hripcsak G,
    2. Schuemie MJ,
    3. Madigan D,
    4. Ryan PB,
    5. Suchard MA
    . Drawing reproducible conclusions from observational clinical data with OHDSI. Yearb Med Inform2021;30:283-9.doi:10.1055/s-0041-1726481. pmid:33882595
    CrossRefPubMedGoogle Scholar
  23. ↵
    1. Li X,
    2. Ostropolets A,
    3. Makadia R,
    4. et al
    . Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ2021;373;n1435.doi:10.1136/bmj.n1435.
    Abstract/FREE Full TextGoogle Scholar
    1. Petersen I,
    2. Douglas I,
    3. Whitaker H
    . Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ2016;354:i4515.doi:10.1136/bmj.i4515. pmid:27618829
    FREE Full TextGoogle Scholar
  25. ↵
    1. Fonseca-Rodríguez O,
    2. Fors Connolly AM,
    3. Katsoularis I,
    4. Lindmark K,
    5. Farrington P
    . Avoiding bias in self-controlled case series studies of coronavirus disease 2019. Stat Med2021;40:6197-208.doi:10.1002/sim.9179. pmid:34470078
    CrossRefPubMedGoogle Scholar
  26. ↵
    1. Sharples LD,
    2. Kirkwood BR
    . Essentials of medical statistics. J R Stat Soc Ser A Stat Soc1989;152:263doi:10.2307/2982934.
    CrossRefGoogle Scholar
  27. ↵
    1. Suchard MA,
    2. Simpson SE,
    3. Zorych I,
    4. Ryan P,
    5. Madigan D
    . Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul2013;23.doi:10.1145/2414416.2414791. pmid:25328363
    CrossRefPubMedGoogle Scholar
  28. ↵
    1. Musonda P,
    2. Farrington CP,
    3. Whitaker HJ
    . Sample sizes for self-controlled case series studies. Stat Med2006;25:2618-31.doi:10.1002/sim.2477. pmid:16372391
    CrossRefPubMedWeb of ScienceGoogle Scholar
  29. ↵
    bc-coordinator. Priority list of adverse events of special interest: COVID-19. 2020. https://brightoncollaboration.us/priority-list-aesi-covid/ (accessed 11 Mar 2021).

  30. ↵
    Center for Biologics Evaluation and Research Office of Biostatistics and Epidemiology. CBER Surveillance Program Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring Protocol. www.bestinitiative.org/wp-content/uploads/2021/02/C19-Vaccine-Safety-AESI-Background-Rate-Protocol-FINAL-2020.pdf (accessed 11 Mar 2021).

  31. ↵
    Food and Drug Administration. Briefing Document. Pfizer-BioNTech COVID-19 Vaccine. In: Vaccines and Related Biological Products Advisory Committee Meeting. www.fda.gov/media/144245/download (accessed 15 September 2021)

  32. ↵
    1. Knoll MD,
    2. Wonodi C
    . Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet2021;397:72-4.doi:10.1016/S0140-6736(20)32623-4 pmid:33306990
    CrossRefPubMedGoogle Scholar
  33. ↵
    1. Sadoff J,
    2. Le Gars M,
    3. Shukarev G,
    4. et al
    . Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med2021;384:1824-35.doi:10.1056/NEJMoa2034201. pmid:33440088
    CrossRefPubMedGoogle Scholar
  34. ↵
    1. Márquez Loza AM,
    2. Holroyd KB,
    3. Johnson SA,
    4. Pilgrim DM,
    5. Amato AA
    . Guillain-Barré Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial: Temporal Associations Do Not Imply Causality. Neurology2021;10.1212/WNL.0000000000011881.doi:10.1212/WNL.0000000000011881. pmid:33824169
    CrossRefPubMedGoogle Scholar
  35. ↵
    Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults. NCT04516746. National Library of Medicine (US). https://clinicaltrials.gov/ct2/show/NCT04516746 [cited 2021 Apr 1]

  36. ↵
    Food and Drug Administration. Briefing Document. Moderna COVID-19 Vaccine. In: Vaccines and Related Biological Products Advisory Committee Meeting. www.fda.gov/media/144434/download

  37. ↵
    1. Klein NP,
    2. Lewis N,
    3. Goddard K,
    4. et al
    . Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA2021;326:1390-9.doi:10.1001/jama.2021.15072. pmid:34477808
    CrossRefPubMedGoogle Scholar
  38. ↵
    1. Renoud L,
    2. Khouri C,
    3. Revol B,
    4. et al
    . Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. JAMA Intern Med2021;181:1243-5.doi:10.1001/jamainternmed.2021.2219. pmid:33904857
    CrossRefPubMedGoogle Scholar
  39. ↵
    1. Sato K,
    2. Mano T,
    3. Niimi Y,
    4. Toda T,
    5. Iwata A,
    6. Iwatsubo T
    . Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database. Int J Infect Dis2021;111:310-2.doi:10.1016/j.ijid.2021.08.071. pmid:34492394
    CrossRefPubMedGoogle Scholar
  40. ↵
    1. Wan EYF,
    2. Chui CSL,
    3. Lai FTT,
    4. et al
    . Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis2022;22:64-72.doi:10.1016/S1473-3099(21)00451-5. pmid:34411532
    CrossRefPubMedGoogle Scholar
  41. ↵
    1. Li X,
    2. Gao L,
    3. Tong X,
    4. et al
    . Autoimmune conditions following mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccination: a descriptive cohort study among 1.1 million vaccinated people in Hong Kong.MedRxiv2021:21265314.doi:10.1101/2021.10.21.21265314
    Abstract/FREE Full TextGoogle Scholar
  42. ↵
    1. Patone M,
    2. Handunnetthi L,
    3. Saatci D,
    4. et al
    . Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med2021;27:2144-53.doi:10.1038/s41591-021-01556-7. pmid:34697502
    CrossRefPubMedGoogle Scholar
  43. ↵
    1. Woo EJ,
    2. Mba-Jonas A,
    3. Dimova RB,
    4. Alimchandani M,
    5. Zinderman CE,
    6. Nair N
    . Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021. JAMA2021;326:1606-13.doi:10.1001/jama.2021.16496. pmid:34617967
    CrossRefPubMedGoogle Scholar
  44. ↵
    1. Paterson RW,
    2. Brown RL,
    3. Benjamin L,
    4. et al
    . The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain2020;143:3104-20.doi:10.1093/brain/awaa240. pmid:32637987
    CrossRefPubMedGoogle Scholar
  45. ↵
    1. Varatharaj A,
    2. Thomas N,
    3. Ellul MA,
    4. et al.,
    5. CoroNerve Study Group
    . Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry2020;7:875-82.doi:10.1016/S2215-0366(20)30287-X. pmid:32593341
    CrossRefPubMedGoogle Scholar
  46. ↵
    1. Stowe J,
    2. Andrews N,
    3. Wise L,
    4. Miller E
    . Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol2009;169:382-8.doi:10.1093/aje/kwn310. pmid:19033158
    CrossRefPubMedWeb of ScienceGoogle Scholar
  47. ↵
    1. Webb AJ,
    2. Brain SA,
    3. Wood R,
    4. Rinaldi S,
    5. Turner MR
    . Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. J Neurol Neurosurg Psychiatry2015;86:1196-201.doi:10.1136/jnnp-2014-309056. pmid:25540247
    Abstract/FREE Full TextGoogle Scholar
  48. ↵
    1. Wouk J,
    2. Rechenchoski DZ,
    3. Rodrigues BCD,
    4. Ribelato EV,
    5. Faccin-Galhardi LC
    . Viral infections and their relationship to neurological disorders. Arch Virol2021;166:733-53.doi:10.1007/s00705-021-04959-6. pmid:33502593
    CrossRefPubMedGoogle Scholar
https://www.bmj.com/content/376/bmj-2021-068373

wrbtrader
 
UK Study Links COVID Vaccines to Neurological Disorders
By Ralph Ellis

Oct. 27, 2021 -- A study conducted in the United Kingdom found that people vaccinated against COVID-19 may have neurological conditions such as Guillain-Barre Syndrome, but that people who actually catch COVID have a much higher chance of having those conditions, the BBC reported.

“The risks of adverse neurological events following SARS-CoV-2 infection are much greater than those associated with vaccinations, highlighting the benefits of ongoing vaccination programs,” concluded the study published in Nature Medicine.

Researchers looked at National Health Service records of 32 million people to trace reactions to COVID vaccinations, the BBC said. The researchers looked at how people fared a month after their first dose of vaccine and a month after testing positive for COVID.

One of the reactions traced was Guillain-Barre Syndrome, a neurological disorder mostly found in people over 50. GBS usually shows up a few days or weeks after a cold, stomach virus, or the flu. In rare cases, surgery or different vaccinations can trigger it. Symptoms include muscle weakness, reflex loss, and numbness or tingling in parts of your body.
  • For vaccinated people, the study found 38 extra cases of GBS for every 10 million adults receiving the Oxford-AstraZeneca vaccine and 60 extra cases of hemorrhagic stroke (brain bleed) for every 10 million adults receiving the Pfizer/BioNTech vaccine, the BBC said.
  • Among people who tested positive for COVID, researchers found 145 extra GBS cases per 10 million with a positive test, 123 extra brain inflammation disorder cases per 10 million people, and 163 extra cases of myasthenia-like disorders per 10 million people.
Brain inflammation cases included encephalitis meningitis and myelitis, or inflammation of the spinal cord. Myasthenia-like disorders included immune conditions affecting the nerves and muscles.

A study of a smaller population in Scotland found the same link between GBS and the AstraZeneca vaccine but they didn’t find increased risks for people who received the Pfizer vaccine, the BBC said.
wrbtrader
 
Operation Warp Speed

On May 15, 2020, President Donald Trump officially announced the public-private partnership.[4][1][9] The purpose of Operation Warp Speed was to coordinate Health and Human Services-wide efforts, including the NIH ACTIV partnership for vaccine and therapeutic development, the NIH RADx initiative for diagnostic development, and work by BARDA.[1]

Operation Warp Speed was formed to encourage private and public partnerships to enable faster approval and production of vaccines during the COVID-19 pandemic.[2] The name was inspired by terminology for faster-than-light travel used in the Star Trek fictional universe, evoking a sense of rapid progress.[10][11]
  • The Food and Drug Administration announced on June 30, 2020, that a vaccine would need to be at least 50% effective for diminishing the severity of COVID-19 symptoms to obtain regulatory and marketing approval.[12]
In January 2021, White House press secretary Jen Psaki announced that the program was expected to undergo a restructure and renaming under the Biden administration.[13][14] Also in January 2021, Dr. Moncef Slaoui, former Operation Warp Speed lead, was told not to use the name Operation Warp Speed anymore.[15] At the end of February 2021, responsibilities of Operation Warp Speed were transferred into the White House COVID-19 Response Team.[7][16]
Operation Warp Speed: implications for global vaccine security

Summary

Several global efforts are underway to develop COVID-19 vaccines, and interim analyses from phase 3 clinical testing have been announced by nine organisations: Pfizer, the Gamaleya Research Institute of Epidemiology and Microbiology, Moderna, AstraZeneca, Sinopharm Group, Sinovac Biotech, Johnson & Johnson, Novavax, and CanSino Biologics. The US programme known as Operation Warp Speed provided US$18 billion in funding for development of vaccines that were intended for US populations.

Depending on safety and efficacy, vaccines can become available through mechanisms for emergency use, expanded access with informed consent, or full licensure. An important question is: how will these Operation Warp Speed vaccines be used for COVID-19 prevention in global health settings? We address some key questions that arise in the transition from US to global vaccine prevention efforts and from ethical and logistical issues to those that are relevant to global vaccine security, justice, equity, and diplomacy...
wrbtrader
 
Last edited:
Study finds no increased risk of rare neurological events after covid vaccination
An increased risk was, however, seen after covid-19 infection

A study of more than eight million people published by The BMJ today finds no increased risk of rare neurological events after covid-19 vaccination.

An increased risk of Bell’s palsy (facial weakness), encephalomyelitis (inflammation of the brain and spinal cord) and Guillain-Barré syndrome (a nerve condition) was, however, seen after covid-19 infection.

Following reports that some people developed Guillain-Barré syndrome after receiving the Oxford-AstraZeneca or Pfizer-BioNTech covid vaccines, the European Medicines Agency listed Guillain-Barré syndrome as a rare side effect of these vaccines. However, so far the results from research into the risk of Guillain-Barré syndrome - and other immune mediated neurological disorders - after covid-19 vaccination have been mixed.

To address this, researchers set out to study the association between covid-19 vaccines, infection with SARS-CoV-2 (the virus responsible for covid-19), and risk of immune mediated neurological events.

Their findings are based on data from two large electronic primary care health record databases in the UK and Spain.
  • They included 8.3 million individuals who received at least one dose of a covid-19 vaccine (Oxford-AstraZeneca, Pfizer-BioNTech, Moderna or Johnson & Johnson) and 735,870 unvaccinated individuals with a positive covid-19 test result.
  • A further 14.3 million people from the general population were also studied retrospectively (before the pandemic) to estimate historical background rates. This group were unvaccinated and had no previous covid, because neither existed at the time.
The events of interest to the research team were four immune mediated neurological disorders: Bell’s palsy (facial weakness), encephalomyelitis (inflammation of the brain and spinal cord), Guillain-Barré syndrome (a nerve condition), and transverse myelitis (inflammation of the spinal cord).

Rates of these disorders were estimated in the 21 days after the first vaccine dose, 90 days after a positive test result, and between 2017 and 2019 for background rates in the general population group.

Overall, the researchers found that post-vaccine rates were consistent with expected (background) population rates for Bell’s palsy, encephalomyelitis and Guillain-Barré syndrome. Rates of transverse myelitis were rare (less than 5 events in all vaccinated groups) so could not be analysed.
More...

Rates of Bell’s palsy, encephalomyelitis and Guillain-Barré syndrome were, however, higher than expected after covid-19 infection.

This is an observational study so can’t establish cause, and the researchers cannot rule out the possibility that unknown differences between groups or misclassification of disorders may have affected their results.

But they point out that several other studies have also reported increased risks of immune mediated neurological events after covid-19 infection, suggesting their results are robust.

As such, they say: “We found no safety signal for any of the studied immune mediated neurological events after vaccination against covid-19. Infection with SARS-CoV-2 was, however, associated with an increased risk of Bell’s palsy, encephalomyelitis, and Guillain-Barré syndrome.”

Further evidence is needed to understand the long term adverse events of vaccination and SARS-CoV-2 infection, while larger cohorts are also needed to study the effect of vaccination on different age groups, particularly among younger populations, they add.

Importantly, all risks - even those observed after SARS-CoV-2 infection - are small in absolute terms for the single individual, write experts in a linked editorial. However, they note that even small absolute risks “can lead to a substantial burden on the healthcare system in the context of mass vaccination and widespread infection.”

Researchers and clinicians have a responsibility to discuss these findings with affected patients and their families, they say, while at the same time acknowledging the inherent uncertainties in making patient level inferences from population level studies.

One approach would be to explain that although neurological conditions do occasionally occur shortly after covid-19 vaccination, good evidence from very large studies shows that these conditions are no more common among vaccinated people than among unvaccinated people.

“We may never be able to tell exactly what caused an individual to develop a neurological condition, but covid-19 vaccination is a highly unlikely reason for most,” they conclude.

[Ends]

Notes for editors
Research: Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis
Editorial: The neurological safety of covid-19 vaccines
wrbtrader
 
You must log in or register to reply here.
Back
Top